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ABSTRACT  
The structurally related AB5-type heat-labile enterotoxins of Escherichia coli and Vibrio 
cholerae are classified into two major types. The type I group includes cholera toxin and E. 
coli LT-I, while the type II subfamily comprises LT-IIa, LT-IIb and LT-IIc. The carbohydrate 
binding specificities of LT-IIa, LT-IIb and LT-IIc are distinctive from those of cholera toxin 
and E. coli LT-I. While CT and LT-I bind primarily to the GM1 ganglioside, LT-IIa binds to 
gangliosides GD1a, GD1b, and GM1, LT-IIb binds only to the GD1a ganglioside, and LT-IIc 
binds to GM1, GM2, GM3 and GD1a. Previous studies of the binding properties of type II B-
subunits have been focused on ganglio core chain gangliosides. To further define the 
carbohydrate binding specificity of LT-IIb B-subunits, we have herein investigated its binding 
to a collection of gangliosides and non-acid glycosphingolipids with different core chains. A 
high affinity binding of LT-IIb B-subunits to gangliosides with neolacto core chain, as e.g. 
NeuGcα3- and NeuAcα3-neolactohexaosylceramide, and NeuGcα3- and NeuAcα3-
neolactooctaosylceramide was detected. An LT-IIb binding ganglioside was isolated from 
human small intestine and characterized as NeuAcα3-neolactohexaosylceramide. The crystal 
structure of B-subunit of LT-IIb with the pentasaccharide moiety of NeuAcα3-
neolactotetraosylceramide (NeuAc-nLT: NeuAcα3Galβ4GlcNAcβ3Galβ4Glc) was 
determined providing the first information for sialic binding site in this sub-family, with clear 
differences with the one from CT and LT-I. 
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Summary statement (25 words) 
LT-IIb, a toxin from diarrhea-causing Escherichia coli binds to sialylated glycoconjugates on 
target tissues, and present only partial similarity with the cholera toxin. 
 
Short title  
Novel carbohydrate-binding site of E. coli heat-labile enterotoxin LT-IIb (74 characters) 
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enterotoxin type IIc; NeuAc-nLT: NeuAcα3Galβ4GlcNAcβ3Galβ4Glc; RT, room 
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INTRODUCTION 
Enterotoxigenic Escherichia coli (ETEC) is the cause of diarrheal diseases leading to several 
hundred million cases of diarrhea and several ten of thousand deaths annually [1]. The 
diarrhea is mainly due to the action of enterotoxins released from the bacteria. ETEC 
produces both heat-stable and heat-labile (LTs) enterotoxins. The LTs belong to AB5 toxins, a 
family of oligomeric proteins consisting of an A-subunit with catalytic activity and a 
pentameric B-subunit responsible for the binding to host glycoconjugates [2, 3]. ETEC 
enterotoxins together with cholera toxin (CT) constitute one of the four subgroups of AB5 
toxins [3]. 
 
The family of ETEC enterotoxins is divided into type I and type II, where the type I B-
subunits are most related to the CT B-subunits. There are three members of the ETEC type II 
heat-labile enterotoxins: LT-IIa, LT-IIb, and LT-IIc. The amino acid sequences of these A-
subunits have only approximately 50-60% identity with the A-subunits of CT/LT type I, and 
there is no amino acid homology between the type II B-subunits and CT/LT type I B-subunits 
[4]. 
 
LTs and CT receptors are mainly gangliosides, a subclass of glycosphingolipids containing 
one or several sialic acid residues. Glycosphingolipids are classified on the basis of their 
carbohydrate core structures. In humans the lacto/type 1 (Galβ3GlcNAc), neolacto/type 2 
(Galβ4GlcNAc), and globo/type 4 (Galα4Gal) core chains are the most common in non-acid 
glycosphingolipids, while gangliosides are mainly based on ganglio (Galβ3GalNAc) or 
neolacto core chains. The primary receptor of B-subunits of CT and LT type I is the GM1 
ganglioside [5], although LT type I also binds to glycoconjugates with terminal N-
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acetyllactosamine [6, 7]. Binding of type II enterotoxin B-subunits have hitherto only been 
tested on gangliosides with ganglio core chain, demonstrating that LT-IIa binds to a range of 
such gangliosides, with highest affinity for the GD1b ganglioside, while LT-IIb interacts 
preferentially with gangliosides GD1a and GT1b [8, 9]. The gangliosides recognized by LT-
IIc are GM1, GM2, GM3 and GD1a [10], with a preference for GM1 with long fatty acyl 
ceramide chain [9]. 
 
While a large amount of CT and LT type 1 structures bound to a variety of glycan receptors 
are available [11-14], the structural data on LT-IIb is limited [4, 15]. The overall structure of 
the LT-IIb holotoxin [4] closely resembles that of CT. Despite of the very limited sequence 
identity, the B-subunit of LT-IIb adopts a very similar fold as the B-subunits of CT and LT 
type 1. The putative ganglioside binding site of LT-IIb was proposed to be located in the same 
region as the GM1 binding sites of CT and LT type I [4]. 
 
In the present work, we further investigated the carbohydrate binding specificity of LT-IIb 
using our unique collection of gangliosides of various core chain series from different sources 
[16], and also a number of related non-acid glycosphingolipids. We also determined the first 
crystal structure of the B-subunit of LT-IIb with a ligand bound, namely with the 
pentasaccharide moiety of NeuAcα3-neolactotetraosylceramide (NeuAc-nLT: 
NeuAcα3Galβ4GlcNAcβ3Galβ4Glc) establishing the molecular basis of the specificity and 
demonstrating the differences with the binding sites of LT-I/CT B-subunits. 
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EXPERIMENTAL PROCEDURES 
 
Production of recombinant LT-IIb B-subunits 
Recombinant LT-IIb B-subunits was produced from a synthetic gene purchased from ATG-
Biosynthetics GmbH (Freiburg, Germany). This gene contained the entire coding sequence 
including the signal sequence.  The signal peptide was removed by reverse PCR and the 
resulting plasmid was pML-LTB2b∆sλcI857. Induction of expression in E. coli strain BL21 
gave rise to inclusion bodies containing the LT-IIb gene product.   
 
25 mL cultures of E. coli BL21 carrying pML-LTB2bΔsλcI857 were grown in 250 mL 
Erlenmeyer flasks in LB broth supplemented with 100 µg/ml ampicillin overnight at 30 °C 
with shaking at 180 rpm. 5 mL aliquots of this culture were used to inoculate 500 mL fresh 
LB broth supplemented with 100 µg/ml ampicillin in 2L Erlenmeyer flasks. The flasks were 
incubated for 2 h at 30 °C with shaking before induction of LT-IIb B-subunit expression by 
raising the temperature to 42 °C. The cultures were incubated for a further 3-4 h, and 
thereafter cells were harvested by centrifugation at 13,000 x g for 20 min, and the pellet was 
stored at -20 °C.  
Cells were resuspended in Tris-HCl, 50 mM, pH 8, and lysed by treatment with lysozyme 
(100 mg/ml) and EDTA (1 mM), at room temperature (RT) for 30 min. MgCl2 was added to a 
final concentration of 10 mM followed by a small amount of DNase (Roche). The mixture 
was incubated for 15 min at RT and a protease inhibitor cocktail was added at a concentration 
recommended by the manufacturer (Complete, Roche). Cells were disrupted by sonication on 
ice for 4-5 min with 2 s pulses at 2 s intervals at 60% amplitude, and the inclusion bodies 
harvested by centrifugation (4,000 x g, 7 min). The pellet was washed with ice cold 
phosphate-buffered saline, pH 7.3 (PBS), containing 0.1 % Triton X114 and re-suspended in 
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minimal volume of double deionized water. Urea solution (6.5 M) was added and left 
overnight with stirring at 4 ˚C. Undissolved debris was then removed by centrifugation at 
48,000 x g for 30 min. The protein was refolded by dialysis overnight at 4 ˚C against 2 L of 
50 mM Carbonate buffer (pH 9) containing 1 M Urea, followed by further extensive dialysis 
again the same buffer containing no urea. Insoluble debris was then removed by 
centrifugation (48,000 x g, 30 min). The supernatant was sterilized by filtration through a 0,22 
µm filter. Assembled protein was purified by ion exchange followed size exclusion 
chromatography. 
 
The protein preparations were analysed on 14 % Tris-Glycine gel (Invitrogen, Carlsbad, CA), 
according to the instructions of the manufacturer, and stained using Coomassie Brilliant Blue 
R-250. 
 
Thermal shift assays 
LT-IIb B-subunit samples were diluted to a final protein concentration of 0.1 mg/mL and 
mixed with SYPRO Orange (5x) in 25 μl. The samples were subjected to thermal denaturation 
using a Real Time PCR machine with a temperature gradient starting at from 25 and 
ascending to 100 °C at a heating rate of 1 °C/min. Protein unfolding was followed by the 
increase of the fluorescence values given by the SYPRO Orange probe. Datapoints are from 
the experimental values and all curves were integrated according to the previously described 
protocol [17]. 
 
Radiolabeling 
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Aliquots of 100 μg of B-subunits were labeled with 125I, using Na125I (100 μCi/ml; 
Amersham Pharmacia Biotech, Little Chalfont, U.K.), according to the IODO-GEN protocol 
of the manufacturer (Pierce, Rockford, IL), giving approximately 5 x 103 cpm/μg protein. 
 
Reference glycosphingolipids 
Total acid and neutral glycosphingolipid fractions were obtained by standard procedures [18]. 
The individual glycosphingolipids were isolated by repeated chromatography on silicic acid 
columns of the native glycosphingolipid fractions, or acetylated derivatives thereof. The 
identity of the purified glycosphingolipids was confirmed by mass spectrometry [19, 20] and 
proton NMR spectroscopy [21]. 
 
Thin-layer chromatography 
Precoated silica gel 60 HPTLC plates with either a glass or aluminium support (Merck, 
Darmstadt, Germany) were used for thin-layer chromatography. The solvent system used for 
separation of glycosphingolipids was chloroform/methanol/water 60:35:8 (by volume). 
Glycosphingolipids were detected by the anisaldehyde reagent [22] or the resorcinol reagent 
[23]. 
 
Chromatogram binding assay 
Binding of radiolabeled LT-IIb B-subunits to glycosphingolipids separated on thin-layer 
chromatograms was performed as described [7]. In short, 20 - 40 μg of mixtures of 
glycosphingolipids, or 20 ng - 4 μg of pure compounds, were separated on aluminium-backed 
thin-layer plates. Dried chromatograms were dipped for 1 min in diethylether/n-hexane (1:5, 
by volume) containing 0.5% (w/v) polyisobutylmethacrylate (Aldrich Chem. Comp. Inc., 
Milwaukee, WI). After drying, the chromatograms were soaked in PBS, containing 2% 
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bovine serum albumin and 0.1% NaN3 (BSA/PBS), for 2 h at RT. Thereafter the plates were 
incubated with 125I-labeled B-subunits diluted in BSA/PBS (1-2 x 106 cpm/ml) for another 2 h 
at RT. After washing six times with PBS, and drying, the thin-layer plates were 
autoradiographed for 12 h using XAR-5 x-ray films (Eastman Kodak, Rochester, NY). 
 
Isolation of human small intestinal gangliosides recognized by LT-IIb B-subunits 
One total acid glycosphingolipid fraction from human small intestine (675 mg) was separated 
by repeated silicic acid chromatography, and followed by repeated chromatography on 
Iatrobeads (Iatrobeads 6RS-8060; Iatron Laboratories, Tokyo) columns, eluted with 
chloroform/methanol/water 60:35:8 (by volume), and finally chloroform/methanol/water 
40:40:12 (by volume). Throughout the separation procedures, aliquots of the fractions 
obtained were analyzed by thin-layer chromatography, and fractions that were coloured green 
by anisaldehyde were tested for binding of LT-IIb using the chromatogram binding assay. The 
fractions were pooled according to the mobility on thin-layer chromatograms and their LT-IIb 
binding activity.  
 
LC-ESI/MS of the LT-IIb binding acid glycospingolipid fractions from human small 
intestine 
Aliquots (20 μg) of ganglioside fractions A-1 and A-2 from human small intestine were 
dissolved in methanol:acetonitrile 75:25 (by volume), and separated on a 200x0.150 mm 
column, packed in-house with 5 μm polyamine II particles (YMC Europe GmbH, Dinslaken, 
Germany). An autosampler, HTC-PAL (CTC Analytics AG, Zwingen, Switzerland) equipped 
with a cheminert valve (0.25 mm bore) and a 2 µl loop was used for sample injection. An 
Agilent 1100 binary pump (Agilent technologies, Palo Alto, CA) delivered a flow of 250 
µl/min, which was split down in an 1/16” microvolume-T (0.15 mm bore) (Vici AG 
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International, Schenkon, Switzerland) by a 50 cm x 50 µm i.d. fused silica capillary before the 
injector of the autosampler, allowing approximately 2-3 µl/min through the column. Samples 
were eluted with an aqueous gradient (A:100% acetonitrile to B: 10 mM ammonium 
bicarbonate). The gradient (0-50% B) was eluted for 40 min, followed by a wash step with 
100% B, and equilibration of the column for 20 min. The samples were analyzed in negative 
ion mode on a LTQ linear quadrupole ion trap mass spectrometer (Thermo Electron, San José, 
CA), with an IonMax standard ESI source equipped with a stainless steel needle kept at –3.5 
kV. Compressed air was used as nebulizer gas. The heated capillary was kept at 270 °C, and 
the capillary voltage was –50 kV. Full scan (m/z 500-1800, two microscan, maximum 100 ms, 
target value of 30,000) was performed, followed by data-dependent MS2 scans (two 
microscans, maximun 100 ms, target value of 10.000) with normalized collision energy of 
35%, isolation window of 2.5 units, activation q= 0.25 and activation time 30 ms). The 
threshold for MS2 was set to 500 counts.  
 
Data acquisition and processing were conducted with Xcalibur software (Version 2.0.7). 
Manual assignment of glycosphingolipid sequences was done with the assistance of the 
Glycoworkbench tool (Version 2.1), and by comparison of retention times and MS2 spectra of 
reference glycosphingolipids. 
 
Crystallization and data collection  
A solution of LT-IIb B-subunit (10 mg ml-1) in sodium carbonate 50 mM pH 9 was sent to the 
High Throughput Crystallization laboratory (HTXlab, EMBL Grenoble, France) to screen for 
the best crystallization conditions. The protein was tested against the JCSG (Qiagen), Wizard 
I and II (Rigaku reagents), PACT (Qiagen), PEGS I (Qiagen), and plates 4 and 5 (Hampton) 
screens.  The crystallization conditions that resulted in good quality crystals were reproduced 
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in house with the addition of 11 mM NeuAc-nLT (Sialyl-Lacto-N-tetraose from 
Elicityl, Crolles, France) to the crystallization buffer. After optimization, high quality crystals 
were obtained in 0.2 M KCl, 20% w/v PEG 3350 and 0.1 M sodium cacodylate pH 6. 
Diffraction data for the LT-IIb/NeuAc-nLT complex was collected to 1.72 Å on ID23-2 
beamline using a Pilatus detector at the ESRF, Grenoble. Diffraction images were integrated 
using XDS program [24], and all further processing done using the CCP4 program suite [25]. 
 
Structure determination and refinement 
The structure was solved by molecular replacement with PHASER [26] using the coordinates 
from the B-pentamer of the LT-IIb structure (PDB ID 1TII) as search model. The initial 
model was optimized using ARP/wARP [27] prior restrained maximum likelihood refinement 
with REFMAC 5.8 [28] iterated with manual rebuilding in Coot [29]. Five percent of the 
observations were set aside for cross-validation analysis, and hydrogen atoms were added in 
their riding positions and used for geometry and structure-factor calculations. Incorporation of 
the ligand was performed after inspection of the 2Fo-Fc weighted maps. Water molecules, 
introduced automatically using Coot, were inspected manually. The quality of the models was 
assessed using the PDB validation server (http://wwpdb-validation.wwpdb.org/validservice/) 
and coordinates were deposited in the Protein Data Bank under code 5G3L. 
 
RESULTS 
 
Recombinant expression and purification of LT-IIb B-subunits 
The LT-IIb B-subunit was isolated in high yield, i.e. 30 mg of protein was obtained from 2 L 
culture medium. The purified protein migrated as a single band, and the apparent molecular 
weight of the monomeric protein was in agreement with the predicted molecular mass of 
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~11.8 kDa (Figure S1 in Suppl. Mat., lanes 3-5). The pentameric form of the LT-IIb B-
subunit appears to run at a molecular weight of approximately 50 kDa in agreement with the 
predicted molecular mass (Figure S1 in Suppl. Mat., lanes 7-9). The protein was stable in 
several of the solvents tested, allowing us to store it in the refrigerator at 4 ºC for weeks, 
without seeing a change in its activity. The protein thermostability and its buffer preference 
was determined using thermal shift assays, showing the highest Tm, of 77 ºC in HEPES buffer 
pH 8.5 with 20 mM NaCl (Figure S2 in Suppl. Mat.). 
 
Binding of LT-IIb B-subunits to mixtures of gangliosides 
First the binding of radiolabeled LT-IIb B-subunits to mixtures of acid and non-acid 
glycosphingolipid fractions from various sources was tested. Thereby a distinct binding to 
some slow-migrating compounds in the acid fractions from rabbit thymus (Figure 1B, lane 1) 
and human neutrophils (Figure 1B, lane 2) was obtained. The binding-active gangliosides 
migrated at the level of sialyl-neolactotetraosylceramide (Figure 1, lane 7) and sialyl-
neolactohexaosylceramide (Figure 1 lane 8), both of which were also recognized by the B-
subunits. Taken together, this suggested a recognition of gangliosides with neolacto core 
chains, since this core chain is predominant among the gangliosides of both rabbit thymus and 
human neutrophils [30-33]. Binding of LT-IIb B-subunits to a minor slow-migrating 
compound in the acid fractions of human small intestine was also observed (Figure 1B, lanes 
3-5).  
 
Binding of LT-IIb B-subunits to reference gangliosides 
Next, the binding of radiolabeled LT-IIb B-subunits to a collection of variant gangliosides 
[18] was examined (Figure 2 and Figures S3 and S4 in Suppl. Mat.). The results of the 
binding assays are summarized in Table 1). As reported previously [8, 9] the B-subunits 
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bound to the GD1a ganglioside, while no binding to the GD1b or GT1b gangliosides was 
obtained.  
 
In addition, the B-subunits of LT-IIb bound to a number of gangliosides with neolacto core, 
as NeuAcα3- and NeuGcα3-neolactotetraosylceramide, NeuAcα3- and NeuGcα3-
neolactohexaosylceramide, NeuAcα3- and NeuGcα3-neolactooctaosylceramide, the G-10 
ganglioside  and the G9-B ganglioside. Binding to the VIM-2 ganglioside was also 
occasionally obtained. However, several gangliosides with neolacto core were not recognized. 
Thus, a terminal disialyl unit, as in NeuAcα8NeuAcα3-neolactotetraosylceramide was not 
tolerated, and the gangliosides with terminal α6-linked sialic acid (NeuAcα6-
neolactotetraosylceramide and NeuAcα6-neolactohexaosylceramide) were not recognized. 
Furthermore, no binding to gangliosides with a sialyl-Lex epitope occurred. Other non-
binding compounds were the gangliosides GM1, GM3, GM2, GD3 and NeuAcα3-
globotetraosylceramide (not shown). No binding of LT-IIb to non-acid glycosphingolipids as 
e.g. neolactotetraosylceramide or gangliotetraosylceramide occurred, demonstrating that the 
terminal α3-linked sialic acid of NeuAcα3-/NeuGcα3-neolactotetraosylceramide and the 
GD1a ganglioside, is necessary for for LT-IIb carbohydrate binding. 
 
Binding of LT-IIb B-subunits to dilutions of gangliosides 
Dilutions of gangliosides on thin-layer chromatograms were used for estimation of the 
relative binding affinities of LT-IIb for the binding active gangliosides. Here. NeuGcα3-
neolactohexaosylceramide was the preferred ligand with a detection limit at less than 20 ng 
(Figure S5B, lane 10), while the detection limits for NeuAcα3-neolactotetraosylceramide and 
the GD1a ganglioside were approximately 800 ng (Figure S5A, lane 3).  
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Human small intestinal ganglioside recognized by LT-IIb B-subunits 
The slow-migrating LT-IIb B-subunit binding ganglioside of human small intestine was 
isolated by repeated chromatographies on silicic acid and Iatrobeads columns, and the 
preparative procedure was monitored by binding of radiolabeled LT-IIb B-subunits on thin-
layer chromatograms. Finally, two LT-IIb binding fractions were obtained and designated 
fractions A-1 and A-2 (Figure 3B, lanes 1 and 2), while the following non-binding fractions 
were designated A-3 and A-4 (Figure 3B, lanes 3 and 4). 
 
LC-ESI/MS of the human small intestinal ganglioside recognized by LT-IIb B-subunits 
The base peak chromatogram obtained by LC-ESI/MS of the LT-IIb binding ganglioside 
fraction A-2 from human small intestine had two [M-2H+]2- ions at m/z 721 and m/z 941, 
respectively (not shown). The major [M-2H+]2- ion at m/z 721 corresponded to a [M-H+]-  ion 
at m/z 1442, indicating a ganglioside with two NeuAc, two Hex, and d18:1-16:0 ceramide, 
and the mass spectrum obtained by MS2 spectrum of the ion at m/z 721 was characteristic for 
the GD3 ganglioside (data not shown). 
 
The [M-2H+]2- ion at m/z 941 corresponded to a [M-H+]- ion at m/z 1882, and indicated a 
ganglioside with one NeuAc, two HexNAc, four Hex, and d18:1-16:0 ceramide. MS2 of the 
[M-2H+]2- ion at m/z 941 (Figure 3C) gave a series of Y ions (Y0 at m/z 536, Y1 at m/z 698, Y2 
at m/z 860, Y3 at m/z 1063, Y4 at m/z 1225, Y5 at m/z 1428, and Y6 at m/z 1590), which along 
with the B- and C-type ions, demonstrated a ganglioside with NeuAc-Hex-HexNAc-Hex-
HexNAc-Hex-Hex sequence and d18:1-16:0 ceramide. Thus, LC-ESI/MS allowed 
identification of NeuAcα3-neolactohexaosylceramide in the LT-IIb binding ganglioside 
fraction isolated from human small intestine. 
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Crystal structure of LT-IIb in complex with Sialyl-lacto-N-tetraose  
LT-IIb B-subunit gave crystals between one day to one week with either needle or 
parallelipipedic morphology, under different conditions (see Supplementary Table S1). In a 
second step, crystals of LT-IIb B-subunits were optimized manually using 20% peg 3350, 
0.2M KCl and 0.1 M buffer pH 6.0-7.6 and the protein was co-crystallized with NeuAc-nLT 
Data were collected at 1.72 Å resolution and indexed in the orthorhombic space group 
P212121, with unit-cell parameters a = 48.56, b = 68.02, c = 154.52 Å. The Matthews 
coefficient [34] indicated the presence of five monomers in the asymmetric unit. The complex 
structure was solved by molecular replacement with a search for one pentamer using 
coordinates of PDB 1TII as model [4]. X-ray data collection statistics are shown in 
Supplementary Table S2. Monomers have been labelled D to H to follow classical AB5 
nomenclature. The monomers forming the B pentamer are almost identical, with root mean 
square (rmsd) values between 0.24 and 0.14 Å for the 98 equivalent Cα. The pentamer is very 
similar to the one observed for the apo LT-IIb structure used as model with a rmsd of 0.35 Å 
for the 484 equivalent Cα.  
  
Electron density corresponding to carbohydrate ligands was observed in the protein crystal 
structure. Four of these ligands are positioned in the groove formed between loops of region 
12 – 16 of one monomer and region 29 – 36 of an adjacent one (Figure 4). The Neu5Acα2-
3Gal fragment of the NeuAc-nLT ligand could be modeled in the binding sites of monomers 
D, G, and H, whereas only the sialic acid moiety could be modelled in monomer E. The rest 
of the ligand was too disordered to be modelled since it was in the solvent area. No density 
was observed in the binding site of monomer F as a result of crystal contacts that would lead 
to steric conflict with the sialic acid moiety. Additional electron density could also identify a 
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sialic acid residue in a non-canonical binding site on the surface or monomer G, not far from 
the occupied binding site in the same monomer (Figure 4).  
 
The groove between WZRmonomers correspond to the expected binding site since 
proteins with OB-fold (a five-stranded closed β barrel) uses the same face and regions to bind 
saccharide or nucleotides [35]. Nevertheless, the binding mode is completely different to the 
one observed for GM1 in LT-I or CT. Since the binding mode is very similar in the four 
occupied sites only monomer D is described in continuation. The terminal Neu5Ac residue of 
NeuAc-nLT establishes most contacts. The pyranose ring of NeuAc is sandwiched between 
the indole ring of Trp92D and the side chain of Asn32E, being stabilized by hydrophobic 
contacts (Figure 5A). Another hydrophobic residue, Ile30E, faces the methyl of the N-
acetylamine group. The oxygen atom at C4 and the N-acetyl group form direct and water 
mediated H-bonds with the Asn31E and Asn32E residues. The carboxylate group of NeuAc 
receives hydrogen bonds from both the side chain hydroxyl group and the main chain amine 
of Thr14D, whereas the deoxy carbon at position 2 of the ring makes an hydrophobic contact 
with the methyl group of Thr13D. The galactose residue presents very limited contact with the 
protein surface, with only one water bridged hydrogen bond from O4 oxygen to Arg12 in 
monomers G and H and to neighboring Asn32 in monomer D. These contacts differ due do 
the two different conformations of the ligand (Supplementary Figure S6). The NeuAc-nLT 
ligand in positions G and H adopts similar conformations, with dihedral angles of φ (O-C2-
O2-C3′) = 47 and 64°, and ψ (C2-O2-C3′-C4′) = 112º and 103° at the NeuAcα2-3Gal linkage, 
whereas a different conformation is seen for monomer D (φ = - 69° and ψ = 110º [36]. 
 
The fifth ligand molecule is observed interacting with monomer G of LT-IIb B-subunit in an 
alternative position. Only the NeuAc residue could be modeled in the electron density. The 
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residue is lying flat in a very shallow domain near the canonical site of monomer G (Figure 
5). The carboxylate groups establish hydrogen bonds with side chains of Arg51G and Tyr55F 
of the neighboring monomer helix, while the glycerol side chains interact with backbone 
nitrogen of Lys53D and Asp54D and with side chain of Tyr55D. Water molecules establish 
several bridged hydrogen bonds, including with the neighboring oligosaccharide in the 
canonical binding site of monomer G.  
 
Due to the divergent orientation of the anomeric oxygen residues, our attempt to model a 
single branched disialylated oligosaccharide, like the GD1a oligosaccharide 
(NeuAcα3Galβ3GalNAcβ4(NeuAcα3)Galβ4Glc), with one sialic acid in each site was not 
successful. However this hypothesis cannot be completely discarded. 
 
 
DISCUSSION AND CONCLUSION 
 
In this study, we have expressed a recombinant LT-IIb B-subunit and investigated the 
carbohydrate binding specificity by means of solid phase glycosphingolipid binding studies. 
By binding to a variety of glycosphingolipids separated on thin-layer chromatograms, we 
found that LT-IIb B-subunits bind with high affinity to gangliosides with neolacto core chain 
as e.g. NeuGcα3- and NeuAcα3-neolactohexa- and neolactooctaosylceramide. Previous 
studies of the carbohydrate recognition by LT-IIb were done using a limited number of 
gangliosides with ganglio core chain, which explains why the LT-IIb binding to neolacto 
based gangliosides was overlooked. Furthermore, by isolating LT-IIb binding gangliosides 
from human small intestine, we established the link between the NeuAc-neolacto gangliosides 
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presence on the target tissue and the LT-IIb infection of intestinal cells, where the protein 
recognition of these antigens promotes the initial steps of the disease. 
 
Lymphocytes are also target cells of LT-IIb, since this protein is a potent adjuvant. 
Interestingly, the immune responses induced by LT-IIa and LT-IIb are distinctive from those 
induced by CT or LT-I [37]. While CT and LT-I induce Th2 responses to co-administered 
antigens, LT-IIa and LT-IIb give a more balanced Th1/Th2 response. These differences have 
been attributed to the binding of the B-subunits to different ganglioside receptors on 
lymphocytes [38]. The available data about human lymphocyte gangliosides structures is very 
limited. However, NeuAc-GM3 is the major ganglioside of both peripheral blood 
lymphocytes and monocytes, and these cells also have NeuAc-neolactotetraosylceramide [39, 
40]. Thus, the identified NeuAcα3-neolacto binding of LT-IIb may also have a role in the 
immunomodulatory activities of the protein. 
 
The crystal structure of LT-IIb was solved in complex with the carbohydrate moiety of the 
newly identified ligand NeuAc-neolactotetraosylceramide. Due to the high flexibility of this 
linear pentasaccharide, only the terminal Neu5Acα2-3Gal disaccharide was observed in most 
binding sites. Sialic acid binds in the groove that was predicted to be the binding site, based 
on the i) overall fold similarity of OB proteins; ii) surface analysis of the crystal structure of 
the apo-protein; and iii) absence of ganglioside binding in mutants affecting the loop in region 
13 and 14 lining the groove [15]. Indeed Thr13 and Thr14 were found critical of GD1a 
affinity [41], and we demonstrate here that the hydroxyl side chain of Thr14 gives a strong 
hydrogen bond to the sialic acid carboxylate group, with the methyl group of Thr13 making 
also hydrophobic contacts with the CH2 at position 2 of NeuAc ring. 
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While the NeuAc binding site in LT-IIb is similarly positioned as those observed in CT and 
LT-I [3] the orientation of the glycan ligand (and therefore the network of contacts) is entirely 
different (Figure 6 and Figure S7 in Suppl. Mat.). The NeuAc in LT-IIb is rotated about 120° 
compared to the one in CT, accompanied with a sliding of the ring. The conformation of GM1 
in CT could not be accommodated in LT-IIb binding site due to the conformation adopted by 
loop 30-35 (31-36 in CT). This loop conformation makes the binding site tighter in that 
position when compared with CT, efficiently tucking the NeuAc residue in that particular 
orientation. There are considerable differences - size and conformation wise - between loops 
50-54 of LT-IIb and the corresponding (51-60) in CT. In CT, this loop is considerably bigger 
forming a second wall of a trench/gate, where the other end of the GM1 interacts.  
 
A secondary binding site with affinity for blood group determinants has been identified on the 
side of the β-barrel of  CT and LT-I B-subunits [14, 42]. However, a secondary binding site in 
the vicinity of the primary site, and accommodating the same ligand, has not previously been 
found in the B-subunits of V. cholerae or ETEC. In this respect LT-IIb resembles the Shiga-
like toxins from E. coli where there are three carbohydrate binding sites in each B-subunit, 
providing an increased binding affinity to the globotriasylceramide receptor [43, 44]. 
However, at the present time, it is not clear if the secondary binding site could accommodate 
the second NeuAc of a divalent ligand such as GD1a or if it would bind to different sialylated 
glycolipids on cell surfaces. Our attempts to fit the two NeuAc residues of a single GD1a 
oligosaccharides in the two sites were not successful, so the second hypothesis seems to be 
more likely.  
 
 
 
 20
 
AUTHOR CONTRIBUTIONS  
Dani Zalem, João P. Ribeiro and Annabelle Varrot carried out the experimental work. All 
authors contributed to the design of the experimental plans, and analyzed the data. Michael 
Lebens, João P. Ribeiro, Anne Imberty and Susann Teneberg wrote the manuscript.  
 
ACKNOWLEDGEMENTS  
The authors are grateful to European Synchrotron Radiation Facility, Grenoble, France for 
access to beamline ID23-2. The use of the LTQ linear quadrupole ion trap mass spectrometer 
(obtained by a grant from the Swedish Research Council (No. 342-2004-4434) is gratefully 
acknowledged. 
 
FUNDING INFORMATION 
This study was supported by the Swedish Research Council (Grant No. 12628), the Swedish 
Cancer Foundation, and governmental grants to the Sahlgrenska University Hospital.  The 
authors also acknowledge the received funding from the European Community's 7th 
Framework Programme (FP7/2007-2013) under the Marie Curie International Outgoing 
Fellowship for Career Development (PIOF-GA-2011-298910), BioStruct-X (grant agreement 
N°283570), the ERASynbio program SynGlycTis (ANR-14-SYNB-0002-02) grants, and to 
the Labex Arcane for the financial support (ANR-11-LABX-0003-01).  
 
 
 
 21
REFERENCES 
 
1. Qadri, F., Svennerholm, A.M., Faruque, A.S., and Sack, R.B. (2005) Enterotoxigenic 
Escherichia coli in developing countries: epidemiology, microbiology, clinical features, 
treatment, and prevention. Clin. Microbiol. Rev. 18, 465-483 
2. Fan, E., Merritt, E.A., Verlinde, C.L., and Hol, W.G. (2000) AB(5) toxins: structures and inhibitor 
design. Curr. Opin. Struct. Biol. 10, 680-686 
3. Beddoe, T., Paton, A.W., Le Nours, J., Rossjohn, J., and Paton, J.C. (2010) Structure, 
biological functions and applications of the AB5 toxins. Trends Biochem. 35, 411-418 
4. van den Akker, F., Sarfaty, S., Twiddy, E.M., Connell, T.D., Holmes, R.K., and Hol, W.G. 
(1996) Crystal structure of a new heat-labile enterotoxin LT-IIb. Structure 4, 665-678 
5. Holmgren, J. (1973) Comparison of the tissue receptors for Vibrio cholerae and 
Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid. Infect. 
Immun. 8, 851-859 
6. Orlandi, P.A., Crithley, D.R., and Fishman, P.H. (1994) The heat-labile enterotoxin of Escherichia 
coli binds to polylactosaminoglycan-containing receptors in CaCo-2 human intestinal epithelial 
cells. Biochemistry 33, 12886-12895 
7. Teneberg, S., Hirst, T.R., Ångström, J., and Karlsson, K.-A. (1994) Comparison of the glycolipid-
binding specificities of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: 
identification of a receptor-active non-ganglioside glycolipid for the heat-labile toxin in infant 
rabbit small intestine. Glycoconj. J. 11, 533-540 
8. Fukuta, S., Magnani, J.L., Twiddy, E.M., Holmes, R.K., and Ginsburg, V. (1988) Comparison of the 
carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins 
LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56, 1748-1753 
 22
9. Berenson, C.S., Nawar, H.F., Kruzel, R.L., Mandell, L.M., and Connell, T.D. (2013) Ganglioside-
binding specificities of E. coli enterotoxin LT-IIc: Importance of long-chain fatty acyl ceramide. 
Glycobiology 23, 23-31 
10. Nawar, H.F., King-Lyons, N.D., Hu, J.C., Pasek, R.C., and Connell, T.D. (2010) LT-IIc, a new 
member of the type II heat-labile enterotoxin family encoded by an Escherichia coli strain 
obtained from a nonmammalian host. Infect. Immun. 78, 4705-4713 
11. Sixma, T.K., Pronk, S.E., Kalk, K.H., van Zanten, B.A.M., Berghuis, A.M., and Hol, W.G.J. 
(1992) Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography. Nature 355, 
561-564 
12. Merritt, E.A., Sarfaty, S., van den Akker, F., L´Hoir, C., Martial, J.A., and Hol, W.G.J. (1994) 
Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 
3, 166-175 
13. Merritt, E.A., Kuhn, P., Sarfarty, S., Erbe, J.L., Holmes, R.K., and Hol, W.G.J. (1998) The 1.25 Å 
resolution refinement of the cholera toxin B-pentamer: evidence of peptide backbone strain at the 
receptor-binding site. J. Mol. Biol. 282, 1043-1059 
14. Heggelund, J.E., Burschowsky, D., Björnestad, V.A., Hodnik, V., Anderluh, G. and Krengel, U. 
(2016) High-resolution crystal structures elucidate the molecular basis of cholera blood group 
dependence. PLoS Pathog. 12 (4), e1005567. 
15. Cody, V., Pace, J., Nawar, H.F., King-Lyons, N., Liang, S., Connell, T.D., and Hajishengallis, G. 
(2012) Structure-activity correlations of variant forms of the B pentamer of Escherichia coli type 
II heat-labile enterotoxin LT-IIb with Toll-like receptor 2 binding. Acta Crystallogr. D Biol. 
Crystallogr. 68, 1604-1612 
16. Roche, N., Ångström, J., Hurtig, M., Larsson, T., Borén, T., and Teneberg, S. (2004) Helicobacter 
pylori and complex gangliosides. Infect. Immun. 72, 1519-1529 
 23
17. Dupeux, F., Rower, M., Seroul, G., Blot, D. and Marquez, J. A. (2011) A thermal stability assay 
can help to estimate the crystallization likelihood of biological samples. Acta Crystallogr D Biol 
Crystallogr. 67, 915-919 
18. Karlsson, K.-A. (1987) Preparation of total non-acid glycolipids for overlay analysis of receptors 
for bacteria and viruses and for other studies. Meth. Enzymol. 138, 212-220 
19. Samuelsson, B.E., Pimlott, W., and Karlsson, K.-A. (1990) Mass spectrometry of mixtures 
of intact glycosphingolipids. Meth. Enzymol. 193, 623-646 
20. Karlsson, H., Halim, A., and Teneberg, S. (2010) Differentiation of glycosphingolipid-
derived glycan structural isomers by liquid chromatography-mass spectrometry. 
Glycobiology 20, 1103-1116 
21. Koerner, Jr., T.A.W., Prestegard, J.H., Demou, P.C., and Yu, R.K. (1983) High-resolution 
proton NMR studies of gangliosides. 1. Use of homonuclear spin-echo J-correlated 
spectroscopy for determination of residue composition and anomeric configurations. 
Biochemistry 22, 2676-2687 
22. Waldi, D. (1962) Sprühreagentien für die dünnschicht-chromatographie. In: Stahl, E., 
editor: Dünnschicht-Chromatographie. Berlin: Springer-Verlag: pp. 496-515 
23. Svennerholm, L., and Fredman, P. (1980) A procedure for the quantitative isolation of 
brain gangliosides. Biochim. Biophys. Acta. 617, 97-109 
24. Kabsch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 
25. Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, 
R.M., Krissinel, E.B., Leslie, A.G.W., McCoy, A., McNicholas, S.J., Mursudov, G.N., 
Pannu, N.S., Potterton, E.A., Powell, H.R., Read, R.J., Vagin, A., and Wilson, K.S. (2011) 
Overview of the CCP4 suite and current development. Acta Crystallogr. D Biol. 
Crystallogr. 67, 235-242 
 24
26. McCoy, J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L., and Read, R.J. (2007) 
Phaser crystallographic softvare. J. App. Crystal. 40, 658-674 
27. Langer, G., Cohen, S.X., Lamzin, V.S., and Perrakis, A. (2008) Automated macromolecular model 
building for X-ray crystallography using ARP/wARP version 7. Nat. Prot. 3, 1171-1179 
28. Murshudov, G.N., Skubák, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, 
M.D., Long, F., and Vagin, A.A. (2011) REFMAC5 for the refinement of macromolecular crystal 
structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 
29. Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010) Features and development of Coot. 
Acta Crystallogr. D. D66, 485-501 
30. Iwamori, M., and Nagai, Y. (1981) Ganglioside composition of rabbit thymus. Biochim. Biophys. 
Acta 665, 205-213 
31. He, P., Hu, J., and Macher, B.A. (1993) Glycosphingolipids of rabbit, sheep and pig thymus. Arch. 
Biochem. Biophys. 305, 350-361 
32. Stroud, M.R., Handa, K., Salyan, M.E.K., Ito, K., Levery, S.B., Hakomori, S.-i., Reinhold, B.B., 
and Reinhold, V.N. (1996) Monosialogangliosides of human myelogenous leukemia HL60 cells 
and normal human leukocytes. 1. Separation of E-selectin binding from nonbinding gangliosides, 
and absence of sialosyl-Lex having tetraosyl to octaosyl core. Biochemistry 35, 758-769 
33. Stroud, M.R., Handa, K., Salyan, M.E.K., Ito, K., Levery, S.B., Hakomori, S.-i., Reinhold, 
B.B., and Reinhold, V.N. (1996) Monosialogangliosides of human myelogenous leukemia 
HL60 cells and normal human leukocytes. 2. Characterization of E-selectin binding 
fractions, and structural requirements for physiological binding to E-selectin. Biochemistry 
35, 770-778 
34. Matthews, B.W. (1968) Solvent content of protein crystals, J Mol Biol, 33, 491 
 25
35. Murzin, A.G. (1993) OB(oligonucleotide/oligosaccharide binding)-fold: common structural and 
functional solution for non-homologous sequences. EMBO J. 12, 861-867 
36 . Imberty, A., and Pérez, S. (2000) Structure, conformation, and dynamics of bioactive 
oligosaccharides: Theoretical approaches and experimental validations. Chem. Rev. 100, 4567-
4588 
37. Hajishengallis, G., and Connell, T.D. (2013) Type II heat-labile enterotoxins: structure, 
function, and immunomodulatory properties. Vet. Immunol. Immunopathol. 152, 68-77 
38. Acre, S., Nawar, H.F., Russell, M.W., and Connell, T.D. (2005) Differential binding of 
Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in 
apoptosis, proliferation, and activation of lymphoid cells. Infect: Immun. 73, 2718-2727 
39. Macher, B.A., Klock, J.C., Fukuda, M.N., and Fukuda, M. (1981) Isolation and structural 
characterization of human lymphocyte and neutrophil gangliosides. J. Biol. Chem. 256, 1968-1974 
40. Kiguchi, K., Henning-Chubb, C.B., and Huberman, E. (1990) Glycosphingolipid patterns 
of peripheral blood lymphocytes, monocytes, and granulocytes are cell specific. J. 
Biochem. 107, 8-14 
41. Connell, T.D., and Holmes, R.K. (1995) Mutational analysis of the ganglioside binding 
activity of the type II Escherichia coli heat-labile enterotoxin LT-IIb. Mol. Microbiol. 16, 
21-31 
42. Holmner, A., Askarieh, G., and Krengel, U. (2007) Blood group antigen recognition by 
Escherichia coli heat-labile enterotoxin. J. Mol. Biol. 371, 754-764 
43. Ling, H., Pannu, N.S., Boodhoo, A., Armstrong, G.D., Clark, C.G., Brunton, J.L. and 
Read, R.J. (2000) A mutant Shiga-like toxin Iie bound to its receptor Gb3: structure of a 
group II Shiga-like toxin with altered binding specificity. Structure 8, 253-264 
 26
44. Soltyk, A.M., MacKenzie, C.R., Wolski, V.M., Hirama, T., Kitov, P.I., Bundle, D.R., and 
Brunton, J.L. (2002) A mutational analysis of the globotriaosylceramide-binding sites of 
verotoxin VT1. J. Biol. Chem. 277, 5351-5359 
45. Barone, A., Säljö, K., Benktander, J., Blomqvist, M., Månsson, J.E., Johansson, B.R., 
Mölne, J., Aspegren, A., Björquist, P., Breimer, M.E., and Teneberg, S. (2014) Sialyl-
lactotetra: a novel cell surface marker of undifferentiated human pluripotent stem cells. J. 
Biol. Chem. 289, 18846-18859 
 
 
FIGURE LEGENDS 
 
Figure 1. Binding of LT-IIb B-subunits to mixtures of gangliosides.  Thin-layer 
chromatogram after detection with anisaldehyde (A), and autoradiogram obtained by binding 
of radiolabeled LT-IIb B-subunits (B). The chromatograms were eluted with 
chloroform/methanol/water 60:35:8 (by volume), and the binding assays were done as 
described under "Experimental procedures". The lanes were: Lane 1, Acid glycosphingolipids 
of rabbit thymus, 20 μg; Lane 2, Acid glycosphingolipids of human neutrophils, 40 μg; Lane 
3, Acid glycosphingolipids of human small intestine (Individual I), 40 μg; Lane 4, Acid 
glycosphingolipids of human small intestine (Individual II), 40 μg; Lane 5, Acid 
glycosphingolipids of human small intestine (Individual III), 40 μg; Lane 6, Reference GM3 
ganglioside (NeuAcα3Galβ4Glcβ1Cer), 4 μg; Lane 7, Reference NeuAcα3-
neolactotetraosylceramide (NeuAcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 μg; Lane 8, 
Reference NeuGcα3-neolactohexaosylceramide 
(NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 2 μg. 
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Figure 2. Binding of LT-IIb B-subunits to reference gangliosides. Thin-layer 
chromatograms after detection with anisaldehyde (A), and autoradiogram obtained by binding 
of radiolabeled LT-IIb B-subunits (B). The chromatograms were eluted with 
chloroform/methanol/water 60:35:8 (by volume), and the binding assays were done as 
described under "Experimental procedures". The lanes were: Lane 1, NeuGcα3-
neolactohexaosylceramide (NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 1 
μg; Lane 2, G9-B ganglioside 
(Galα3(Fucα2)Galβ4GlcNAcβ6(NeuAcα3Galβ4GlcNAcβ3)Galβ4GlcNAcβ3Galβ4Glcβ1Ce
r), 4 μg; Lane 3, NeuAc-GD1a (NeuAcα3Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer), 4 μg; 
Lane 4, NeuAc-GD1b (Galβ3GalNAcβ4(NeuAcα8NeuAcα3)Galβ4Glcβ1Cer), 4 μg; Lane 5, 
NeuAc-GT1b (NeuAcα3Galβ3GalNAcβ4(NeuAcα8NeuAcα3)Galβ4Glcβ1Cer), 4 μg. 
Figure 3. Characterization of LT-IIb binding gangliosides from human small intestine 
(fraction A-2). (A and B) Binding of LT-IIb B-subunits to human small intestinal 
gangliosides. Thin-layer chromatogram after detection with anisaldehyde (A), and 
autoradiogram obtained by binding of radiolabeled LT-IIb B-subunits (B). The 
chromatograms were eluted with chloroform/methanol/water 60:35:8 (by volume), and the 
binding assays were done as described under "Experimental procedures". The lanes were: 
Lane 1, Fraction A-1 from human small intestine, 4 μg; Lane 2, Fraction A-2 from human 
small intestine, 4 μg; Lane 3, Fraction A-3 from human small intestine, 4 μg; Lane 4, Fraction 
A-4 from human small intestine, 4 μg; Lane 5, NeuGcα3-neolactohexaosylceramide 
(NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 1 μg; Lane 6, NeuAc-GD1a 
(NeuAcα3Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer), 4 μg. (C) MS2 of m/z 941 from LC-
ESI/MS of fraction A-2.  (D) Interpretation formula showing the deduced ganglioside 
sequence. 
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Figure 4. LT-IIb B pentamer with NeuAc-nLT bound. Overall representation of the 
pentamer of subunit B of LT-IIb with the monomers colored by chain. Display of 2Fo-Fc 
weighted electron density map electron density for the ligands at 1σ (0.41 eA3) 
 
Figure 5.  Zoomed in view at the binding of NeuAc-nLT at monomer G. A : Cartoon 
representation of the primary and “secondary” binding sites of LT-IIb with the bound NeuAc-
nLT, whose partial structure is shown in stick representation. The LT-IIb residues interacting 
with the ligand are displayed in green and the formed H-bonds as blue lines. Protein backbone 
is colored as a function of the monomer. Not all water molecules are shown for simplicity 
(Note: All highlighted residues belong to monomer G except for Tyr55F). B: Surface 
representation of the surface highlighting the deep NeuAc primary binding site, and the 
shallow secondary one. Surfaces are colored according to protein monomer. 
 
Figure 6. Comparison of fold and glycan binding site in CT and LT pentamers of B-
subunit.  Green : LT-IIb complexed with terminal NeuAcα3-neolactohexaosylceramide (this 
work), yellow LT-I and and pink GM1 complexed with GM1 pentasaccharide (code 2XRQ 
and 3CHB respectively). All binding sites are displayed with same orientation of the protein 
beneath. 
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Table 1.  Glycosphingolipid binding of LT-IIb B-subunits 
No. Trivial name Structure Binding Source 
Simple compounds    
1. NeuAc-GM3 NeuAcα3Galβ4Glcβ1Cer -a Human intestine 
2. NeuAc-GD3 NeuAcα8NeuAcα3Galβ4Glcβ1Cer - Bovine buttermilk 
3. LacCer Galβ4Glcβ1Cer - Dog intestine 
Lacto/neolacto series    
4. nLc4 Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Human neutrophils 
5. nLc6 Galβ4GlcNAcβ6(Galβ4GlcNAcβ3)Galβ4Glcβ1Cer -  Bovine buttermilk 
6. H type 2 penta Fucα2Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Human erythrocytes 
7. Lea penta Galβ3(Fucα4)GlcNAcβ3Galβ4Glcβ1Cer -  Human intestine 
8. B type 2 hexa Galα3(Fucα2)Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Human erythrocytes 
9. A type 1 hexa GalNAcα3(Fucα2)Galβ3GlcNAcβ3Galβ4Glcβ1Cer - Human intestine 
10. Leb hexa Fucα2Galβ3(Fucα4)GlcNAcβ3Galβ4Glcβ1Cer - Human meconium  
11. B type 1 hepta Galα3(Fucα2)Galβ3(Fucα4)GlcNAcβ3Galβ4Glcβ1Cer - Monkey intestine 
12. NeuAcα3nLc4  NeuAcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cerb + Human erythrocytes  
13. NeuGcα3nLc4  NeuGcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cerb + Piglet intestine 
14. NeuAcα6nLc4 NeuAcα6Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Human meconium 
15. NeuAc2-nLc4 NeuAcα8NeuAcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Human kidney 
16. NeuAcα3Lc4  NeuAcα3Galβ3GlcNAcβ3Galβ4Glcβ1Cer - Human embryonic stem cellsc 
17. NeuAcα3-Lex NeuAcα3Galβ4(Fucα3)GlcNAcβ3Galβ4Glcβ1Cer - Commercial 
18. NeuAc-Sda GalNAcβ4(NeuAcα3)Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Moose intestine 
19. NeuGc-Sda GalNAcβ4(NeuGcα3)Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Moose intestine 
20. NeuAcα3-nLc6 NeuAcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer +++ Human hepatoma 
21. NeuGcα3-nLc6 NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer +++ Rabbit thymus 
22. NeuAcα3-nLc8 NeuAcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer +++ Human erythrocytes 
23. NeuGcα3-nLc8 NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer +++ Rabbit thymus 
24. VIM-2 NeuAcα3Galβ4GlcNAcβ3Galβ4(Fucα3)GlcNAcβ3Galβ4Glcβ1Cer + Human colon cancer 
25. NeuAcα3-Lex-nLc8 NeuAcα3Galβ4(Fucα3)GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Human pancreas cancer 
26.  Galβ4GlcNAcβ6(NeuAcα6Galβ4GlcNAcβ3)Galβ4Glcβ1Cer -  Bovine buttermilk 
27. Galβ4GlcNAcβ6(NeuAcα6Galβ4GlcNAcβ3)Galβ4GlcNAcβ3Galβ4Glcβ1Cer - Human meconium 
28. NeuAc-G-10 NeuAcα3Galβ4GlcNAcβ6(NeuAcα3Galβ4GlcNAcβ3)Galβ4GlcNAcβ3Galβ4Glcβ1Cer      + Human erythrocytes 
29. G9-B Galα3(Fucα2)Galβ4GlcNAcβ6(NeuAcα3Galβ4GlcNAcβ3)Galβ4GlcNAcβ3Galβ4Glcβ1Cer + 
Human erythrocytes    
Ganglio series    
30. GgO3 GalNAcβ4Galβ4Glcβ1Cer - Guinea pig erythrocytes 
31. GgO4 Galβ3GalNAcβ4Galβ4Glcβ1Cer - Mouse intestine 
32. GM2 GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer - Human brain 
33. GM1 Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer - Human brain 
34. GD1a NeuAcα3Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer +++ Human brain 
35. GD1b Galβ3GalNAcβ4(NeuAcα8NeuAcα3)Galβ4Glcβ1Cer - Human brain 
36. GT1b NeuAcα3Galβ3GalNAcβ4(NeuAcα8NeuAcα3)Galβ4Glcβ1Cer - Human brain 
Globo series    
37. Gb3 Galα4Galβ4Glcβ1Cer - Human erythrocytes 
38. Gb4 GalNAcβ3Galα4Galβ4Glcβ1Cer - Human erythrocytes 
39. Forssman GalNAcα3GalNAcβ3Galα4Galβ4Glcβ1Cer - Dog intestine 
40. NeuAcα3-Gb4 NeuAcα3GalNAcβ3Galα4Galβ4Glcβ1Cer - Human embryonic stem cellsc 
a) Binding is defined as follows: +++ denotes an intense and highly reproducible staining when 4 μg of the glycosphingolipid was applied on the thin-layer chromatogram,  
+ denotes an occasional staining, while - denotes no binding even at 4 μg. 
b) The NeuAc/NeuGcα3Galβ4GlcNAc and NeuAcα3Galβ3GalNAc sequences are underlined. 
c) Binding of LT-IIb to compounds 16 and 40 was evaluated using the slow-migrating ganglioside fraction from human embryonic stem cells (fraction 181C) [45]. 
 
 
SUPPLEMENTARY MATERIAL 
 
Biochemical and structural characterization of the novel sialic acid-binding 
site of Escherichia coli heat-labile enterotoxin LT-IIb  
 
 
Table S1. Successful crystallization conditions from assays at High Throughput 
Crystallization laboratory (HTXlab, Grenoble, France) using LT-IIb B-subunit (10 mg ml-1) 
in sodium carbonate 50 mM pH 9. 
 
Salt pH, buffer Precipitant 
(w/v) 
Morphology 
LiCl 1 M  Trisodium acetate 0.1M, pH 4 20% PEG 6000  
Needle-like LiCl 1 M Citric acid 0.1M, pH 4 30% PEG 6000 
LiCl 1 M Citric acid 0.1M, pH 5 30% PEG 6000 
MgCl2 0.2M Sodium cacodylate/ 
HCl 0.1M, pH 6.5 
20% PEG 1000  
 
 
 
Single crystal 
Na2HPO4 0.2M - 20% PEG 3350 
Na2SO4 0.2M Bis-tris propane 0.1M 20% PEG 3350 
KCl 0.2M - 20% PEG 3350 
KI 0.2M - 20% PEG 3350 
KSCN 0.2M - 20% PEG 3350 
K/Na tartare 0.2M - 20% PEG 3350 
Trisodium  
citrate 0.2M 
- 20% PEG 3350 
- Citric acid 0.1M, pH 4 (NH4)2SO4 1.6M 
 
 	   	  
Table S2. X-ray data collection and refinement statistics  
 
	  
	  
	  
  
Data Collection 
Space group P 21 21 21 
Cell dimensions 
          a, b, c (Å), α, β, γ (deg) 
 
48.56, 68.02, 154.51, 90.0, 90.0, 90.0 
Nb. reflections 271309 
Nb. Unique reflections 54271 
          resolution (Å) 48.56 – 1.72 (1.75-1.72) 
          Rmerge (within I+/I-) 0.07 (0.47) 
          I/σ(I) (within I+/I-) 2.89 (3.00) 
         Completeness (%) 98.4 (96.4) 
         redundancy 5.0 (4.5) 
  
Refinement 
Resolution (Å) 46.33 – 1.72   
Nb. Reflections 
Nb free reflections 
51509 
2713 
Rwork 17.1 
Rfree 19.6 
rms deviation 
          bond  lengths (Å) 
          bond angles (deg) 
 
0.018 
1.714 
Chain  D E  F  G  H 
Nb Atoms protein 768 750 749 747 750 
                  ligand 32 21 NA 53 32 
                  water 143 117 100 119 110 B	  factor	  protein 17.6 17.1 16.9 16.7 15.5 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ligand 31.6 34.9  30.6 21.0 
              water 27.8 27.4 26.2 28.3 29.1 
Ramachandran Allowed 
                         Favored 
                         Outliers 
99 
100 
0 
PDB Code 5G3L 
 	  	   	  
Figure S1. Purified recombinant LT-IIb B-subunits.  LT-IIb B-subunit preparation 
separated on a 14 % Tris-Glycine gel and stained using Coomassie Brilliant Blue R-250. Lane 
1, molecular mass standards; lane 2, boiled CTB; lane 3, boiled LTB-IIb; lane 4, boiled LTB-
IIb; lane 5, boiled LTB-IIb; lane 6, unboiled CTB; lane 7, unboiled LTB-IIb; lane 8, unboiled 
LTB-IIb; lane 9, unboiled LTB-IIb. When the pentamer is boiled, it denatures into monomers, 
with a predicted molecular mass of ~11.8 kDa 	  	  
	  	  	  	  	  	  	  	  	  
Figure S2. Thermal shift assay (TSA) data for LT-IIb B-subunit (derived curved). Two 
inflections are seen. The first regards the pentamer dissociation (around 46 ºC) while the 
second represents the monomer unfolding, which takes place at higher temperatures. A small 
Tm variation (72 – 77 ºC) is seen in these tested conditions. The data for the protein in water 
pH 7.3 solution is shown in a light blue color; water + 20mM NaCl, in dark blue; HEPES pH 
8.5, in pink; and HEPES + 20mM NaCl, in grey. 
 	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  
Figure S3. Binding of LT-IIb B-subunits to reference gangliosides . Thin-layer 
chromatograms after detection with resorcinol (A), and autoradiogram obtained by binding of 
radiolabeled LT-IIb B-subunits (B). The chromatograms were eluted with 
chloroform/methanol/water 60:35:8 (by volume), and the binding assays were done as 
described under "Experimental procedures". The lanes were: Lane 1, NeuAc-GD1a 
(NeuAcα3Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer), 4 µg; Lane 2, NeuGcα3-
neolactohexaosylceramide (NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 
µg; Lane 3, NeuAc-G-10 ganglioside 
(NeuAcα3Galβ4GlcNAcβ6(NeuAcα3Galβ4GlcNAcβ3)Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 
µg; Lane 4, NeuGcα3-neolactohexaosylceramide 
(NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), and NeuGcα3-
neolactooctaosylceramide 
(NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; Lane 5, 
NeuAcα3-neolactooctaosylceramide 
(NeuAcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; Lane 6, 
VIM-2 ganglioside (NeuAcα3Galβ4GlcNAcβ3Galβ4(Fucα3)GlcNAcβ3Galβ4Glcβ1Cer), 4 
µg; Lane 7, NeuAcα3-Lex-neolactooctaosylceramide 
(NeuAcα3Galβ4(Fucα3)GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; Lane 8, 
NeuAcα6-neolactohexaosylceramide 
(Galβ4GlcNAcβ6(NeuAcα6Galβ4GlcNAcβ3)Galβ4Glcβ1Cer), 4 µg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Binding of LT-IIb B-subunits to reference gangliosides. Thin-layer 
chromatograms after detection with resorcinol (A), and autoradiogram obtained by binding of 
radiolabeled LT-IIb B-subunits (B). The chromatograms were eluted with 
chloroform/methanol/water 60:35:8 (by volume), and the binding assays were done as 
described under "Experimental procedures". The lanes were: Lane 1, NeuAcα3-
neolactotetraosylceramide (NeuAcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; Lane 2, 
NeuGcα3-neolactotetraosylceramide (NeuGcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; 
Lane 3, NeuAcα6-neolactotetraosylceramide (NeuAcα6Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 
µg; Lane 4, GM1 ganglioside (Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer), 4 µg, and 
NeuAcα8NeuAcα3-neolactotetraosylceramide 
(NeuAcα8NeuAcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; Lane 5, NeuAcα3-Lex 
(NeuAcα3Galβ4(Fucα3)GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; lane 6, NeuGcα3-
neolactohexaosylceramide (NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 
µg.  
 
 
 
 
 
 
 
 
 
 	  	  
Figure S5. Binding of LT-IIb B-subunits to dilutions of gangliosides. The chromatograms 
were eluted with chloroform/methanol/water 60:35:8 (by volume), and the binding assay was 
done as described under "Experimental procedures". The lanes on (A) were: Lane 1, 
NeuAcα3-neolactotetraosylceramide (NeuAcα3-nLc4, 
NeuAcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), and GD1a ganglioside 
(NeuAcα3Galβ3GalNAcβ4(NeuAcα3)Galβ4Glcβ1Cer), 4 µg each; Lane 2, NeuAcα3-nLc4 
and GD1a, 2 µg each; Lane 3, NeuAcα3-nLc4 and GD1a, 800 ng each; Lane 4, NeuAcα3-
nLc4 and GD1a, 400 ng each; Lane 5, NeuAcα3-nLc4 and GD1a, 200 ng each; Lane 6, 
NeuGcα3-neolactohexaosylceramide (NeuGcα3-nLc6, 
NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer), 4 µg; Lane 7, NeuGcα3-nLc6, 
2 µg; Lane 8, NeuGcα3-nLc6, 800 ng; Lane 9, NeuGcα3-nLc6, 400 ng; Lane 10, NeuGcα3-
nLc6, 200 ng. The lanes on (B) were: Lane 1, NeuAcα3-nLc4 and GD1a 800 ng each; Lane 2, 
NeuAcα3-nLc4 and GD1a, 400 ng each; Lane 3, NeuAcα3-nLc4 and GD1a, 80 ng each; 
Lane 4, NeuAcα3-nLc4 and GD1a, 40 ng each; Lane 5, NeuAcα3-nLc4 and GD1a, 20 ng 
each; Lane 6, NeuGcα3-nLc6, 800 ng; Lane 7, NeuGcα3-nLc6, 400 ng; Lane 8, NeuGcα3-
nLc6, 80 ng; Lane 9, NeuGcα3-nLc6, 40 ng; Lane 10, NeuGcα3-nLc6, 20 ng.  	  
Figure S6. Overlay of the NeuAc-nLT conformations in LT-IIb B-subunit main binding site 
(D and E monomers are shown with yellow and orange carbons, A monomer is displayed with 
green carbons). No water molecules are shown for clarity. 
 
 	  	  	  	  	  	  	  	   	  
Figure S7. Overlay of binding site of LT-IIb (green) and CT (gray)  illustrating the different 
orientation of NeuAc . 
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